LAUSR

Background & Aim Cell- and tissue-based therapeutic approaches are progressively gaining ground in the clinics. Mapping the variations of cell source, processing, and delivery mode of cells and tissues is of the utmost importance for the progression of the field. With the support of five established scientific organizations, this report, the eighth of its kind, describes activity in Europe for the years 2016 and 2017 in the area of cellular and tissue- engineered therapies, excluding hematopoietic stem cell treatments for the reconstitution of hematopoiesis. Methods, Results & Conclusion In 2016 and 2017, a combined 234 teams from 29 countries responded to the cellular and engineered tissue therapy survey; 227 teams reported treating 8236 patients in these two years. Indications were hematology/oncology (predominantly prevention or treatment of GvHD and HSC graft enhancement; 43%), musculoskeletal/rheumatological disorders (29%), cardiovascular disorders (6%), neurological disorders (4%), gastrointestinal disorders (